An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Start Date
4/15/2026
Completion Date
12/1/2032
Summary
This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
Eligibility Criteria
Age Range: 18 years to No maximum
Conditions
Locations
University of Colorado
Aurora, Colorado 80045
United States
Midwest Allergy Sinus Asthma
Normal, Illinois 61761
United States
Institute for Allergy and Asthma
Wheaton, Maryland 20902
United States
Brigham and Women's Allergy and Clinical Immunology, Mass General Brigham Healthcare Center (Chestnut Hill)
Chestnut Hill, Massachusetts 02467
United States
University of Michigan Allergy Clinic
Ann Arbor, Michigan 48105
United States
Washington University of St. Louis
St Louis, Missouri 63130
United States
University of Utah
Salt Lake City, Utah 84112
United States